ALNY
Alnylam Pharmaceuticals Inc
224.40$
+0.2%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -7,288.6% | -457.5% | -288.4% | -91.5% | 386.1% | 68.1% | -71.8% | -84.3% | -105.2% | -173.3% | -145.6% | -327.6% | -460.2% | -652.5% | -425.7% | -751.1% | -126.7% | -124.8% | -76.0% | -52.2% | 5.7% | -0.4% | 14.1% | |
| – | 476.1% | 57.1% | 54.6% | 14.2% | 8.0% | 6.0% | 6.0% | 4.9% | 6.2% | 13.5% | 21.7% | 23.6% | 46.4% | 32.1% | 14.9% | 8.6% | 24.7% | 15.1% | 10.6% | 4.3% | 3.0% | 2.5% | 1.5% | |
| – | – | 96.0% | – | 30.8% | 28.4% | 18.7% | 20.1% | 19.3% | 20.3% | 18.5% | 43.9% | 65.4% | 111.4% | 160.2% | 103.2% | 210.6% | 79.6% | 28.4% | 19.6% | 22.2% | 12.1% | 12.1% | 9.4% | |
| – | – | – | – | – | 6.9% | 2.7% | – | 25.6% | 25.2% | -12.4% | 44.3% | -13.0% | 113.8% | 153.1% | 108.6% | 248.7% | 91.8% | 31.8% | 26.5% | 29.7% | – | – | – | |
| – | 1,651.1% | 81.4% | 293.2% | -9.9% | 499.9% | 66.4% | -50.1% | -79.5% | -67.6% | -13.4% | -17.2% | -58.1% | 85.4% | 36.5% | -3.2% | 60.2% | 183.1% | -2.6% | -19.3% | -3.4% | 0.6% | -9.5% | -12.0% | |
| – | 1,772.2% | 210.5% | 34.1% | 18.5% | 15.3% | 11.2% | 4.9% | 4.7% | 1.6% | 12.5% | 8.5% | 17.7% | 31.5% | 136.9% | 115.9% | 169.4% | 63.8% | 14.3% | 9.0% | 6.9% | 3.4% | 1.5% | 1.6% | |
| – | -1,840.9% | -808.7% | -707.1% | -111.6% | -545.1% | 18.7% | 14.4% | 17.8% | 99.0% | 5.1% | -276.7% | -1,085.4% | -781.9% | 302.4% | -322.9% | 364.4% | -190.1% | -88.4% | -32.4% | 16.3% | -18.4% | -5.2% | 11.7% | |
| – | – | – | – | – | – | – | – | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | 3.7% | 0.9% | -0.5% | -2.9% | -31.6% | -0.9% | -1.3% | -0.3% | -4.6% | 388.3% | 60.9% | 29.2% | 25.0% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | 296.7% | 365.0% | 318.1% | -133.5% | -40.0% | -13.7% | 40.6% | 59.2% | 24.5% | 0.0% | 0.0% | -14.7% | |
| – | 13,470.5% | 1,191.6% | 920.5% | 618.8% | 115.2% | 3.3% | 3.5% | 3.7% | 0.9% | 140.0% | 426.0% | 1,456.6% | 1,499.3% | 377.1% | 1,251.1% | 87.4% | 374.6% | 201.9% | 147.7% | 41.0% | 9.4% | 13.1% | -8.2% | |
| – | 4,384.1% | -68.3% | -79.0% | 416.6% | -44.8% | 90.1% | -54.0% | -62.8% | -5.3% | -28.2% | 3.7% | 43.5% | 257.2% | 27.0% | 502.4% | -299.3% | 57.8% | -10.3% | 38.3% | 4.5% | -2.9% | 6.8% | 18.6% | |
| – | -9,060.8% | -668.0% | -322.5% | -110.0% | 370.8% | 56.9% | -76.7% | -89.0% | -106.8% | -185.8% | -154.1% | -345.3% | -491.7% | -789.4% | -541.6% | -920.5% | -190.5% | -139.1% | -85.0% | -59.1% | 2.3% | -1.9% | 12.5% |
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.